Inscripta, developer of the first scalable platform for benchtop Digital
Genome Engineering, today announced the appointment of Ron McGrath as
Chief Financial Officer. Mr. McGrath has held leadership and financial
roles for more than 25 years in the biotechnology and information
technology industries, most recently at Illumina, the leader in DNA
sequencing technology.
“Ron has tremendous experience in scaling teams and organizations in the
U.S. and internationally, and we believe this will be an invaluable
asset as Inscripta moves forward on the path to commercialization of our
genome engineering platform,” said Kevin Ness, CEO of Inscripta. “His
track record of success is impressive, and I am delighted to welcome him
to the company and look forward to his expert advice and input as we
prepare to launch our platform later this year.”
Before joining Inscripta, Mr. McGrath held a variety of leadership roles
during his 13 years at Illumina, Inc. He served as Vice President of
Finance, building international finance, controllership functions, and
corporate planning, where he closely partnered with the manufacturing,
development, and commercial leadership teams to drive growth and
profitability initiatives. He also served as Chief of Staff in
Operations, with broad responsibilities spanning resource planning and
prioritization, customer and pricing analytics, and gross margin
optimization. Before joining Illumina, he held financial leadership
roles at Memec, LLC, a designer and distributor of semiconductors, and
dj Orthopedics, LLC, a medical device manufacturer, and distributor. Mr.
McGrath holds an MBA from Pepperdine University and a bachelor’s degree
in Quantitative Economics from the University of California, San Diego.
“I am honored to join Inscripta during this exciting phase of growth, as
the company prepares to transform the genome engineering industry,” said
Mr. McGrath. “This team and technology are uniquely positioned to drive
innovation, and I look forward to helping to build the infrastructure
that will deliver value to our customers and shareholders.”
About Inscripta
Inscripta is developing the world’s first scalable platform for benchtop
Digital Genome Engineering. The company’s advanced CRISPR-based
platform, consisting of an instrument, reagents, and software, will
offer a fully automated workflow that enables multiplexed, trackable
editing of cells at an unprecedented scale. Inscripta’s goal is to
empower scientists whose gene editing research is stifled by current
technical and licensing limitations. By providing this unique platform
and engaging in collaborative business practices, such as making its
MAD7 CRISPR nuclease free for research purposes, the company enables
scientists to realize a new era of biological discovery. Headquartered
in Boulder, Colo., with offices in Pleasanton, Calif., and San Diego,
Inscripta is backed by leading investors including Venrock, Foresite,
Mérieux Développement, Paladin Capital Group, MLS Capital, and
NanoDimension. For more information, visit www.inscripta.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190430005378/en/